2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

chlamydia trachomatis infection

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-105099
    Rifalazil

    KRM-1648; ABI-1648

    		 Antibiotic DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
    Rifalazil
  • HY-144820
    JO146

    		Ser/Thr Protease Infection
    JO146 is a Chlamydia trachomatis high temperature requirement A (CtHtrA) protease inhibitor with IC50s of 21.86 and 1.15 μM for CtHtrA and human neutrophil elastase (HNE), respectively. JO146 can be used to inhibits bacterial infections .
    JO146
  • HY-136885
    (S,S)-TAPI-0

    		MMP Infection
    (S,S)-TAPI-0 is a matrix metalloproteinase (MMP) inhibitor that inhibits the growth of Chlamydia trachomatis by inhibiting PDF enzyme activity. (S,S)-TAPI-0 can be used to study Chlamydia infection .
    (S,S)-TAPI-0
  • HY-181614
    CppA-IN-1

    		Bacterial Infection
    CppA-IN-1 is a CppA inhibitor specific to Chlamydia trachomatis, which inhibits the growth of Chlamydia trachomatis. CppA-IN-1 shows no activity against recombinant CppA in vitro. CppA-IN-1 can be used in studies related to Chlamydia trachomatis infection .
    CppA-IN-1
  • HY-120450
    CL-55

    		Bacterial Infection Inflammation/Immunology
    CL-55 is an inhibitor for type three secretion system of Chlamydia trachomatis, that blocks the effector molecules delivery of bacteria into host cells. CL-55 ameliorates the C. trachomatis infection and inflammation in mice .
    CL-55
  • HY-117746
    KSK120

    		Bacterial Infection
    KSK120 is a potent inhibitor of drug-resistant infections with specific activity against Chlamydia trachomatis (C. trachomatis). KSK120 inhibits the developmental cycle of C. trachomatis, thereby reducing the infectivity of progeny bacteria. KSK120 targets the glucose-6-phosphate (G-6P) metabolic pathway of C. trachomatis, showing its potential application in antimicrobial inhibition. The mechanism of KSK120 may involve inhibition of the transcriptional machinery, which provides new ideas for the development of specific drugs against C. trachomatis infection .
    KSK120
  • HY-105099R
    Rifalazil (Standard)

    KRM-1648 (Standard); ABI-1648 (Standard)

    		 Antibiotic Reference Standards DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
    Rifalazil (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: